ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study | Prof Felix Mahfoud

Future of Renal Denervation Devices - Felix Mahfoud - RHC 2014Подробнее

ESC-EAPCI Renal denervation consensus statement overviewПодробнее

Renal denervation and uncontrolled hypertension – evolving data - ESC 2017Подробнее

SPYRAL HTN-ON MED 3 year resultsПодробнее

Journal Club - Dr N Odanovic - Spyral-HTN on Med Trial of Renal Denervation TherapyПодробнее

SPYRAL HTN-ON MED Trial with Prof. MahfoudПодробнее

Can renal denervation reduce cardiovascular events?Подробнее

An Overview of Renal Denervation, Dr. Felix MahfoudПодробнее

EuroPCR 2018: SPYRAL HTN-ON MED - Justin Davies, David KandzariПодробнее

Redefining hypertension management with renal denervation - EuroPCR 2021Подробнее

Future of renal denervation - EuroPCR 2019Подробнее

TCT 22: SYMPLICITY HTN-3: RDN in Pts With Uncontrolled Hypertension | Dr Deepak BhattПодробнее

ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials | Dr Michael J ReardonПодробнее

HF 2022: CLOROTIC: Combined Loop With Thiazide Diuretics in Pts With Decompensated HF | Dr TrullasПодробнее

AHA 22: SPYRAL HTN-ON MED: Renal Denervation in Patients with Hypertension | Dr David KandzariПодробнее

La SEC te lleva a ACC22 [IN] ∙ The SPYRAL HTn-on Med Pilot StudyПодробнее